Abstract:e17004 Background: PARP inhibitors (PARPi) have been approved in the treatment of metastatic castration-resistant prostate cancer with deleterious or suspected deleterious alterations in homologous recombination repair (HRR) genes. Patients carrying alterations of different HRR genes showed diverse response to PARPi, while the underlying mechanism is unrevealed. Homologous recombination deficiency (HRD) score serves as a promising way to interpret the genomic instability by targeted next-generation sequencing (NGS). In this study, we analyzed HRD score and its relationship to genomic characteristics in a prostate cancer (PC) cohort. Methods: Tumor tissue and matched white blood cells from 295 PC patients were analyzed by NGS-based assays, which target over 10,000 single-nucleotide polymorphisms distributed across human genome to characterize genomic instability, as well as the whole coding region of 733 or 233 genes. HRD score was derived by the sum of three indexes, including loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions. Deleterious or suspected deleterious mutations were included for analysis. Tumor mutation burden (TMB) was calculated by the number of somatic single nucleotide variants and indels in examined coding regions, with driver mutations excluded. An ovarian and fallopian tube cancer cohort, carrying deleterious or suspected deleterious mutations in BRCA1/2, was also included. Results: In PC cohort, 25 patients (8.47%) had BRCA1/2 mutations, with additional 39 patients (13.2%) carrying mutations in HRR genes other than BRCA1/2. HRD score was similar among tumors with germline BRCA1/2 mutation (n = 9), somatic BRCA1/2 mutation (n = 14) or both (n = 2) (median HRD score 38.0, 32.5 and 49.5; P = 0.281). In BRCA1/2 mutation carriers, HRD score in PC cohort was lower than ovarian cancer (n = 222) and fallopian tube cancer (n = 8) (median HRD score 36, 54 and 67; P < 0.001). PC samples with CDK12 (n = 35), ATM (n = 13) and PALB2 (n = 2) mutations had lower HRD score compared with BRCA1/2 mutants (median HRD score 24, 14, 11 and 36; P < 0.001). In PC patients without HRR mutation, HRD score was higher in TP53 mutants compared with TP53 wildtype (median HRD score 25 and 14; P < 0.001), while tumors with ERG fusion had lower HRD score than ERG fusion absent tumors (median HRD score 8 and 18.5; P = 0.029). In four TP53 mutated PC patients treated with PARPi in our center, three patients achieved PSA response. Furthermore, no linear correlation was discovered between TMB and HRD score, while tumors with higher HRD score (HRD score ≥ 30) had a bit lower TMB (median TMB 3.07 vs 3.91, P = 0.002). Conclusions: HRD score was affected by alterations in different HRR genes, TP53 mutation and ERG fusion, which should be taken into consideration of the future clinical trials and research on intrinsic mechanisms. Patients carrying alterations other than HRR genes might benefit from PARPi. Further studies are needed.

Genomic landscape and homologous recombination repair (HRR) genes analysis in Chinese prostate cancer (PCa) patients.

Genomic characteristics of homologous recombination deficiency in prostate cancer.

Homologous recombination repair gene mutations in Chinese pancreatic ductal adenocarcinoma patients.

The clinical value of homologous recombination deficiency score in prostate cancer.

Frequency of homologous recombination-related (HRR) genes mutations in gastric cancer.

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients

Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value

119P A Pan-Cancer Study on Difference of Homologous Recombination Deficiency and Tumour Mutational Burden Between Chinese and Western Patients

Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).

Germline Dna Damage Repair Gene Alterations In Chinese Prostate Patients: More Than Hrr And Mmr.

Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers

Prognostic Value of Genomic Mutations in Metastatic Prostate Cancer

ASO Visual Abstract: Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes among Taiwanese Breast Cancers

Germline Mutations in DNA Repair Genes in a Large Series of Unselected Chinese Prostate Cancer Patients.

Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients

Germline Mutations in Homologous Recombination Repair Genes among Chinese Pancreatic Ductal Adenocarcinoma Patients Detected Using Next‐generation Sequencing

Mutation Landscape Of Genes Involved In Dna-Damage Repair Pathway Among Chinese Patients With Prostate Cancer

Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Characterization Of Mutations In Hrr Genes, Tmb, And Pd-L1 Expression In Chinese Patients With Ovarian Cancer.